Deans' stroke musings: Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Saturday, September 9, 2023

Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis

Maybe your doctor can learn how to cure spasticity in this 45 minute CME

Overburdened, Undertreated: Developments in the Patient-Centered Management of Spasticity in Multiple Sclerosis

0.75 CME

45 MINS

$0 FEE

SAVE

ADD TOPIC TO EMAIL ALERTS

Activity Overview

Over 80% of patients with multiple sclerosis (MS) experience related spasticity. This symptom can be debilitating for both physical and non-physical daily function. Yet, despite the high prevalence and impact of spasticity, a substantial portion of affected patients remain unrecognized and undertreated.

Even when cases are accurately identified, achieving adequate treatment is challenging. Many of the most common therapies are accompanied by unpleasant side effects (e.g., insomnia, muscle weakness) that often lead to their discontinuation. Though botulinum neurotoxin (BoNT) is among those shown to be effective, optimal timing and patient selection are needed to maximize its benefits. The current activity seeks to help clinicians circumvent unpleasant side effects and undertreatment through personalizing and adjusting therapy based on individual patient needs. In collaboration with the Multiple Sclerosis Foundation, 239 patients with MS-related spasticity were surveyed to give deeper insight into evidence-based strategies to improve patient outcomes.

Target Audience

The target audience for this initiative includes general neurologists, physiatrists, nurse practitioners, physician assistants, and other healthcare professionals involved in the diagnosis and long-term management of patients with MS-related spasticity.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Identify concerns and preferences of patients with MS surrounding the experience and treatment of spasticity, and apply this information in the development of improved patient-driven management strategies
Assess diverse presentations of MS-related spasticity to accurately identify patients early in the disease course and intervene accordingly
Determine patient-centered strategies to target individual treatment goals using both non-pharmacological and medication-based approaches
Analyze key considerations for the effective use of BoNT injections to maximize their benefits and ensure patient satisfaction with treatment